Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Assessment of Peripheral Serotonin Synthesis Using Stable Isotope-Labeled Tryptophan.

Gehin M, Welford RWD, Garzotti M, Vercauteren M, Groenen PMA, Nayler O, Sidharta PN, Dingemanse J.

Clin Pharmacol Ther. 2018 Apr 16. doi: 10.1002/cpt.1087. [Epub ahead of print]

PMID:
29663345
2.

A fully automated image analysis method to quantify lung fibrosis in the bleomycin-induced rat model.

Seger S, Stritt M, Vezzali E, Nayler O, Hess P, Groenen PMA, Stalder AK.

PLoS One. 2018 Mar 16;13(3):e0193057. doi: 10.1371/journal.pone.0193057. eCollection 2018.

3.

Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.

Piali L, Birker-Robaczewska M, Lescop C, Froidevaux S, Schmitz N, Morrison K, Kohl C, Rey M, Studer R, Vezzali E, Hess P, Clozel M, Steiner B, Bolli MH, Nayler O.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.370.

4.

S1P1 Modulator-Induced G αi Signaling and β-Arrestin Recruitment Are Both Necessary to Induce Rapid and Efficient Reduction of Blood Lymphocyte Count In Vivo.

Birker-Robaczewska M, Bolli M, Rey M, de Kanter R, Kohl C, Lescop C, Boucher M, Poirey S, Steiner B, Nayler O.

Mol Pharmacol. 2018 Feb;93(2):109-118. doi: 10.1124/mol.117.109140. Epub 2017 Dec 4.

PMID:
29203519
5.

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential.

Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, Hess P, Iglarz M, Clozel M, Nayler O.

J Pharmacol Exp Ther. 2017 Jul;362(1):186-199. doi: 10.1124/jpet.116.239665. Epub 2017 May 5.

6.

MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis.

Bauer Y, White ES, de Bernard S, Cornelisse P, Leconte I, Morganti A, Roux S, Nayler O.

ERJ Open Res. 2017 Mar 22;3(1). pii: 00074-2016. doi: 10.1183/23120541.00074-2016. eCollection 2017 Jan.

7.

Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation.

Welford RW, Vercauteren M, Trébaul A, Cattaneo C, Eckert D, Garzotti M, Sieber P, Segrestaa J, Studer R, Groenen PM, Nayler O.

Sci Rep. 2016 Jul 21;6:30059. doi: 10.1038/srep30059.

8.

Novel S1P1 receptor agonists - Part 4: Alkylaminomethyl substituted aryl head groups.

Lescop C, Müller C, Mathys B, Birker M, de Kanter R, Kohl C, Hess P, Nayler O, Rey M, Sieber P, Steiner B, Weller T, Bolli MH.

Eur J Med Chem. 2016 Jun 30;116:222-238. doi: 10.1016/j.ejmech.2016.03.048. Epub 2016 Mar 23.

PMID:
27061986
9.

Novel S1P1 receptor agonists - Part 5: From amino-to alkoxy-pyridines.

Bolli MH, Lescop C, Birker M, de Kanter R, Hess P, Kohl C, Nayler O, Rey M, Sieber P, Velker J, Weller T, Steiner B.

Eur J Med Chem. 2016 Jun 10;115:326-41. doi: 10.1016/j.ejmech.2016.03.020. Epub 2016 Mar 12.

PMID:
27027817
10.

Reply: the bleomycin model: in pursuit of relevant biomakers.

Bauer Y, Nayler O, Kaminski N.

Am J Respir Cell Mol Biol. 2015 Nov;53(5):748-9. doi: 10.1165/rcmb.2015-0196LE. No abstract available.

11.

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.

Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, Studer R, Vezzali E, Freti D, Hadana H, Schläpfer M, Cattaneo C, Bortolamiol C, Weber E, Whitby BR, Delahaye S, Wanner D, Steiner P, Nayler O, Hess P, Clozel M.

J Cardiovasc Pharmacol. 2015 Nov;66(5):457-67. doi: 10.1097/FJC.0000000000000296.

12.

FTY720 Phosphate Activates Sphingosine-1-Phosphate Receptor 2 and Selectively Couples to Gα12/13/Rho/ROCK to Induce Myofibroblast Contraction.

Sobel K, Monnier L, Menyhart K, Bolinger M, Studer R, Nayler O, Gatfield J.

Mol Pharmacol. 2015 Jun;87(6):916-27. doi: 10.1124/mol.114.097261. Epub 2015 Mar 11.

13.

Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis.

Gatfield J, Mueller Grandjean C, Bur D, Bolli MH, Nayler O.

PLoS One. 2014 Sep 16;9(9):e107809. doi: 10.1371/journal.pone.0107809. eCollection 2014.

14.

A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis.

Bauer Y, Tedrow J, de Bernard S, Birker-Robaczewska M, Gibson KF, Guardela BJ, Hess P, Klenk A, Lindell KO, Poirey S, Renault B, Rey M, Weber E, Nayler O, Kaminski N.

Am J Respir Cell Mol Biol. 2015 Feb;52(2):217-31. doi: 10.1165/rcmb.2013-0310OC.

15.

Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.

Gatfield J, Monnier L, Studer R, Bolli MH, Steiner B, Nayler O.

Cell Signal. 2014 Jul;26(7):1576-88. doi: 10.1016/j.cellsig.2014.03.029. Epub 2014 Apr 2.

PMID:
24704119
16.

Novel S1P(1) receptor agonists--part 3: from thiophenes to pyridines.

Bolli MH, Abele S, Birker M, Bravo R, Bur D, de Kanter R, Kohl C, Grimont J, Hess P, Lescop C, Mathys B, Müller C, Nayler O, Rey M, Scherz M, Schmidt G, Seifert J, Steiner B, Velker J, Weller T.

J Med Chem. 2014 Jan 9;57(1):110-30. doi: 10.1021/jm4014696. Epub 2013 Dec 24.

PMID:
24367923
17.

Novel S1P(1) receptor agonists--part 2: from bicyclo[3.1.0]hexane-fused thiophenes to isobutyl substituted thiophenes.

Bolli MH, Velker J, Müller C, Mathys B, Birker M, Bravo R, Bur D, de Kanter R, Hess P, Kohl C, Lehmann D, Meyer S, Nayler O, Rey M, Scherz M, Steiner B.

J Med Chem. 2014 Jan 9;57(1):78-97. doi: 10.1021/jm401456d. Epub 2013 Dec 17.

PMID:
24345087
18.

Novel S1P1 receptor agonists--part 1: From pyrazoles to thiophenes.

Bolli MH, Müller C, Mathys B, Abele S, Birker M, Bravo R, Bur D, Hess P, Kohl C, Lehmann D, Nayler O, Rey M, Meyer S, Scherz M, Schmidt G, Steiner B, Treiber A, Velker J, Weller T.

J Med Chem. 2013 Dec 12;56(23):9737-55. doi: 10.1021/jm4014373. Epub 2013 Nov 22.

PMID:
24266709
19.

Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator.

Rey M, Hess P, Clozel M, Delahaye S, Gatfield J, Nayler O, Steiner B.

PLoS One. 2013 Sep 12;8(9):e74285. doi: 10.1371/journal.pone.0074285. eCollection 2013.

20.

Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling.

Sobel K, Menyhart K, Killer N, Renault B, Bauer Y, Studer R, Steiner B, Bolli MH, Nayler O, Gatfield J.

J Biol Chem. 2013 May 24;288(21):14839-51. doi: 10.1074/jbc.M112.426726. Epub 2013 Apr 15.

21.

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.

Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O.

PLoS One. 2012;7(10):e47662. doi: 10.1371/journal.pone.0047662. Epub 2012 Oct 15.

22.

Identification of cathepsin L as a potential sex-specific biomarker for renal damage.

Bauer Y, Hess P, Qiu C, Klenk A, Renault B, Wanner D, Studer R, Killer N, Stalder AK, Stritt M, Strasser DS, Farine H, Kauser K, Clozel M, Fischli W, Nayler O.

Hypertension. 2011 Apr;57(4):795-801. doi: 10.1161/HYPERTENSIONAHA.110.157206. Epub 2011 Feb 28.

23.

The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.

Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, Kohl C, Steiner B, Clozel M.

J Pharmacol Exp Ther. 2011 May;337(2):547-56. doi: 10.1124/jpet.110.176487. Epub 2011 Feb 23.

24.

Synthetic sphingosine 1-phosphate receptor modulators--opportunities and potential pitfalls.

Bolli MH, Lescop C, Nayler O.

Curr Top Med Chem. 2011;11(6):726-57. Review.

PMID:
21261590
25.

2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.

Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, Gatfield J, Hess P, Kohl C, Mangold C, Mathys B, Menyhart K, Müller C, Nayler O, Scherz M, Schmidt G, Sippel V, Steiner B, Strasser D, Treiber A, Weller T.

J Med Chem. 2010 May 27;53(10):4198-211. doi: 10.1021/jm100181s.

PMID:
20446681
26.

bFGF induces S1P1 receptor expression and functionality in human pulmonary artery smooth muscle cells.

Birker-Robaczewska M, Studer R, Haenig B, Menyhart K, Hofmann S, Nayler O.

J Cell Biochem. 2008 Nov 1;105(4):1139-45. doi: 10.1002/jcb.21918.

PMID:
18773427
27.

Promotion of sleep by targeting the orexin system in rats, dogs and humans.

Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F.

Nat Med. 2007 Feb;13(2):150-5. Epub 2007 Jan 28.

PMID:
17259994
28.

A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.

Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, Kusic R, Shreeniwas R, Morganti A, Ballmer A, Segal E, Nayler O, Clozel M.

Invest New Drugs. 2007 Jun;25(3):247-52. Epub 2006 Oct 5.

PMID:
17021960
29.

Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.

Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Müller C, Müller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P.

J Pharmacol Exp Ther. 2004 Oct;311(1):204-12. Epub 2004 May 14.

30.

The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma.

Birker-Robaczewska M, Boukhadra C, Studer R, Mueller C, Binkert C, Nayler O.

J Recept Signal Transduct Res. 2003;23(4):289-305.

PMID:
14753294
31.

Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA.

Stoilov P, Daoud R, Nayler O, Stamm S.

Hum Mol Genet. 2004 Mar 1;13(5):509-24. Epub 2004 Jan 6.

PMID:
14709600
32.

Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines.

Ziltener P, Mueller C, Haenig B, Scherz MW, Nayler O.

J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):155-68.

PMID:
12503613
33.

Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122 --> Cys) that alters autoactivation and autodegradation of cationic trypsinogen.

Simon P, Weiss FU, Sahin-Toth M, Parry M, Nayler O, Lenfers B, Schnekenburger J, Mayerle J, Domschke W, Lerch MM.

J Biol Chem. 2002 Feb 15;277(7):5404-10. Epub 2001 Nov 21.

34.

The ER repeat protein YT521-B localizes to a novel subnuclear compartment.

Nayler O, Hartmann AM, Stamm S.

J Cell Biol. 2000 Sep 4;150(5):949-62.

35.

The in vivo minigene approach to analyze tissue-specific splicing.

Stoss O, Stoilov P, Hartmann AM, Nayler O, Stamm S.

Brain Res Brain Res Protoc. 1999 Dec;4(3):383-94.

PMID:
10592349
36.
37.

ScienceLabDatabase: a computer program to organize a molecular biology laboratory.

Nayler O, Stamm S.

Biotechniques. 1999 Jun;26(6):1186-91.

PMID:
10376159
38.
40.

SAF-B protein couples transcription and pre-mRNA splicing to SAR/MAR elements.

Nayler O, Strätling W, Bourquin JP, Stagljar I, Lindemann L, Jasper H, Hartmann AM, Fackelmayer FO, Ullrich A, Stamm S.

Nucleic Acids Res. 1998 Aug 1;26(15):3542-9.

41.

Characterization and comparison of four serine- and arginine-rich (SR) protein kinases.

Nayler O, Stamm S, Ullrich A.

Biochem J. 1997 Sep 15;326 ( Pt 3):693-700.

42.

The proximal pathway of metabolism of the chlorinated signal molecule differentiation-inducing factor-1 (DIF-1) in the cellular slime mould Dictyostelium.

Morandini P, Offer J, Traynor D, Nayler O, Neuhaus D, Taylor GW, Kay RR.

Biochem J. 1995 Mar 15;306 ( Pt 3):735-43.

43.

A localized differentiation-inducing-factor sink in the front of the Dictyostelium slug.

Kay RR, Large S, Traynor D, Nayler O.

Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):487-91.

44.
45.

DIF-1 induces its own breakdown in Dictyostelium.

Insall R, Nayler O, Kay RR.

EMBO J. 1992 Aug;11(8):2849-54.

Supplemental Content

Loading ...
Support Center